Affiliation:
1. Nutrition Program, College of Health Solutions, Arizona State University, Phoenix, AZ 85004, USA
2. Systems Precision Engineering and Advanced Research (SPEAR), Theriome Inc., Phoenix, AZ 85004, USA
Abstract
Depressive disorders are the most prevalent mental health conditions in the world. The commonly prescribed antidepressant medications can have serious side effects, and their efficacy varies widely. Thus, simple, effective adjunct therapies are needed. Vinegar, a fermented acetic acid solution, is emerging as a healthful dietary supplement linked to favorable outcomes for blood glucose management, heart disease risk, and adiposity reduction, and a recent report suggests vinegar may improve symptoms of depression. This randomized controlled study examined the 4-week change in scores for the Center for Epidemiological Studies Depression (CES-D) questionnaire and the Patient Health Questionnaire (PHQ-9) in healthy overweight adults ingesting 2.95 g acetic acid (4 tablespoons vinegar) vs. 0.025 g acetic acid (one vinegar pill) daily. A secondary objective explored possible underlying mechanisms using metabolomics analyses. At week 4, mean CES-D scores fell 26% and 5% for VIN and CON participants respectively, a non-significant difference between groups, and mean PHQ-9 scores fell 42% and 18% for VIN and CON participants (p = 0.036). Metabolomics analyses revealed increased nicotinamide concentrations and upregulation of the NAD+ salvage pathway for VIN participants compared to controls, metabolic alterations previously linked to improved mood. Thus, daily vinegar ingestion over four weeks improved self-reported depression symptomology in healthy overweight adults, and enhancements in niacin metabolism may factor into this improvement.
Funder
Arizona State University Graduate and Professional Student Association
Reference70 articles.
1. GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204–1222.
2. Impact of Major Depressive Disorder on Comorbidities: A Systematic Literature Review;Arnaud;J. Clin. Psychiatry,2022
3. Impact of Treating Depression on Associated Comorbidities: A Systematic Literature Review;Arnaud;Prim. Care Companion CNS Disord.,2023
4. Efficacy and Safety of Antidepressants in Patients with Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis;Stiglbauer;JAMA Psychiatry,2023
5. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: A systematic review and network meta-analysis;Gosmann;Psychol. Med.,2023